Evidence map›Paper›PMID 25008926›Full record

ArticleJournal of virology2014

Impact of HLA selection pressure on HIV fitness at a population level in Mexico and Barbados.

Claudia I Juarez-Molina, Rebecca Payne, Maribel Soto-Nava, Santiago Avila-Rios, Humberto Valenzuela-Ponce, Emily Adland, Ellen Leitman, Jacqui Brener, Maximilian Muenchhoff, Songee Branch and 3 more

Abstract readComparative Study
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Specificity of CD8Vaccines · 2020
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Role of HLA Adaptation in HIV Evolution.Frontiers in immunology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Claudia I Juarez-MolinaDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom claudia_juarez_m@yahoo.co.uk.
Rebecca PayneDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Maribel Soto-NavaCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Santiago Avila-RiosCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Humberto Valenzuela-PonceCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Emily AdlandDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Ellen LeitmanDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Jacqui BrenerDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Maximilian MuenchhoffDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.
Songee BranchLadymeade Reference Unit, Queen Elizabeth Hospital, Bridgetown, Barbados.
Clive LandisLadymeade Reference Unit, Queen Elizabeth Hospital, Bridgetown, Barbados.
Gustavo Reyes-TeranCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico.
Philip GoulderDepartment of Paediatrics, University of Oxford, Oxford, United Kingdom.

Funding

Optimizing CD8+ T-cell responses against C clade HIV infection in subSaharan AfriR01AI046995 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2000 to 2014
$6.8M
NIAID NIH HHS R01 AI046995Wellcome Trust
6 · The paper itself

Abstract

unlabelledPrevious studies have demonstrated that effective cytotoxic T lymphocyte (CTL) responses drive the selection of escape mutations that reduce viral replication capacity (VRC). Escape mutations, including those with reduced VRC, can be transmitted and accumulate in a population. Here we compared two antiretroviral therapy (ART)-naive HIV clade B-infected cohorts, in Mexico and Barbados, in which the most protective HLA alleles (HLA-B*27/57/58:01/81:01) are differentially expressed, at 8% and 34%, respectively. Viral loads were significantly higher in Mexico than in Barbados (median, 40,774 versus 14,200; P < 0.0001), and absolute CD4(+) T-cell counts were somewhat lower (median, 380/mm(3) versus 403/mm(3); P = 0.007). We tested the hypothesis that the disparate frequencies of these protective HLA alleles would be associated with a higher VRC at the population level in Mexico. Analysis of VRC in subjects in each cohort, matched for CD4(+) T-cell count, revealed that the VRC was indeed higher in the Mexican cohort (mean, 1.13 versus 1.03; P = 0.0025). Although CD4 counts were matched, viral loads remained significantly higher in the Mexican subjects (P = 0.04). This VRC difference was reflected by a significantly higher frequency in the Barbados cohort of HLA-B*27/57/58:01/81:01-associated Gag escape mutations previously shown to incur a fitness cost on the virus (P = 0.004), a difference between the two cohorts that remained statistically significant even in subjects not expressing these protective alleles (P = 0.01). These data suggest that viral set points and disease progression rates at the population level may be significantly influenced by the prevalence of protective HLA alleles such as HLA-B*27/57/58:01/81:01 and that CD4 count-based guidelines to initiate antiretroviral therapy may need to be modified accordingly, to optimize the effectiveness of treatment-for-prevention strategies and reduce HIV transmission rates to the absolute minimum. IMPORTANCE: Immune control of HIV at an individual level is strongly influenced by the HLA class I genotype. HLA class I molecules mediating effective immune control, such as HLA-B*27 and HLA-B*57, are associated with the selection of escape mutants that reduce viral replicative capacity. The escape mutants selected in infected patients can be transmitted and affect the viral load and CD4 count in the recipient. These findings prompt the hypothesis that the frequency of protective alleles in a population may affect viral set points and rates of disease progression in that population. These studies in Mexico and Barbados, where the prevalence rates of protective HLA alleles are 8% and 34%, respectively, support this hypothesis. These data suggest that antiretroviral therapy (ART) treatment-for-prevention strategies will be less successful in populations such as those in Mexico, where viral loads are higher for a given CD4 count. Consideration may therefore usefully be given to ART initiation at higher absolute CD4 counts in such populations to optimize the impact of ART for prevention.

Indexed as

Virus ReplicationAdultBarbadosCD4 Lymphocyte CountCohort StudiesFemaleHIV-1HIV InfectionsHLA-B AntigensHumansImmune EvasionMaleMexicoMiddle AgedRacial GroupsViral LoadHLA-B Antigens

Identifiers

PMID25008926
PMCPMC4178877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.